Table 2 Comparisons between patients treated with and without PMX-DHP
|  | PMX-DHP –(median (range), n = 17) | PMX-DHP + (median (range), n = 14) | p value |
|---|---|---|---|
Age, years | 71 (50, 84) | 66.5 (52, 81) | 0.109 |
Sex, male/female | 15/2 | 13/1 | 0.999 |
Smoking, never/ex/current | 3/13/1 | 1/10/3 | 0.346 |
Pack-year of smoking | 25 (0, 80) | 45 (0, 81) | 0.086 |
Period from symptom onset to AE, mo | 72 (0, 203) | 30 (2, 156) | 0.082 |
Observation period, mo | 66 (9, 205) | 50 (2, 162) | 0.463 |
%FVC before AE, % | 46.7 (37.5, 89.3) | 61.9 (40.7, 88.0) | 0.136 |
FEV1% before AE, % | 87.5 (79.7, 100.0) | 87.4 (78.5, 107.0) | 0.769 |
%DLCO before AE, % | 57.1 (33.5, 88.2) | 62.0 ( 44.0, 77.8) | 0.892 |
PaO2 at rest before AE, Torr | 68.5 (53.9, 86.6) | 72.8 (49.0, 91.0) | 0.978 |
6MWT distance before AE, m | 375 (160, 465) | 365 (175, 507) | 0.523 |
6MWT minSpO2 before AE, % | 82 (62, 83) | 82 (60, 87) | 0.721 |
Serum LDH at AE, IU/L | 322 (220, 601) | 347 (277, 602) | 0.409 |
Serum KL-6 at AE, U/mL | 1367 (634, 3160) | 1690 (481, 6404) | 0.174 |
Serum SP-D at AE, ng/mL | 295 (24, 645) | 469 (102, 966) | 0.159 |
Extent scores on HRCT before AE (full score: 25) | 11.5 (7, 19) | 13 (7, 15) | 0.624 |
HRCT-patterns at AE, peripheral/multifocal/diffuse/unknown | 1/2/13/1 | 3/1/10/0 | 0.483 |
The GAP staging system before AE, I/II/III/unknown | 2/3/7/5 | 6/5/3/0 | 0.059 |
Preceding treatment for IPF, +/- | 10/7 | 8/6 | 0.925 |
Preceding oxygen therapy, +/- | 5/12 | 4/10 | 0.999 |
P/F ratio at AE | 162 (44, 316) | 171 (31, 368) | 0.741 |
Extent scores on HRCT at AE (full score: 25) | 20 (13, 25) | 20.5 (14, 25) | 0.915 |
Period from admission to commencement of treatments for AE, day | 1 (0, 6) | 0.5 (0, 17) | 0.755 |
Administration of steroid-pulse therapy for AE, +/- | 17/0 | 14/0 | NS. |
Administration of Immunosuppresants for AE, +/- | 12/5 | 9/5 | 0.709 |
Administration of Sivelestat sodium hydrate for AE, +/- | 3/14 | 5/9 | 0.413 |
Intubation at AE, +/- | 3/14 | 5/9 | 0.413 |